-
03:58:41 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

GILD Stock News

10/03/22 9:00 AM
Nasdaq : GILD
fda approval
Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product
Kite, a Gilead Company, today announced the U.S. Food and Drug Administration has approved the company's retroviral vector manufacturing facility in Oceanside, California, for commercial production. Over 10,000 patients have been treated with Kite' s CAR T-cell therapies globally through more than 300 authorized treatment centers around the world,...
RHEA-AI
very positive
09/22/22 8:30 AM
Nasdaq : GILD
Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines
Gilead Sciences, Inc. today announced a new public-private initiative with the Partnership for Health Advancement in Vietnam, a collaboration between Brigham and Women' s Hospital, Harvard Medical School and Beth Israel Deaconess Medical Center. This multi-year initiative will have a phased approach to help address barriers that limit viral hepatitis...
RHEA-AI
positive
09/16/22 7:00 AM
Nasdaq : GILD
Kite's CAR T-cell Therapy Yescarta(R) First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Kite, a Gilead Company, today announces that the European Medicines Agency Committee for Medicinal Products for Human Use has issued a positive opinion for Yescarta (R) for adult patients with diffuse large B-cell lymphoma and high-grade B-cell lymphoma that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.
RHEA-AI
positive
09/16/22 6:39 AM
Nasdaq : GILD
covid-19
CHMP Adopts Positive Opinion to Extend Indication of Veklury(R) (Remdesivir) for the Treatment of Pediatric Patients with COVID-19
Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion to extend the indication of Veklury (R) for the treatment of pediatric patients who do not require supplemental oxygen and are at increased risk of progressing to severe COVID-19 and pediatric patients...
RHEA-AI
neutral
09/15/22 6:21 PM
Nasdaq : GILD
covid-19
WHO Expands Recommendation for Veklury(R) (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline
The WHO conditional recommendation for Veklury' s use in the treatment of patients with severe COVID-19 is mainly driven by the final results of the WHO- sponsored SOLIDARITY study, which showed a statistically significant 17% lower relative risk of death or progression to needing ventilation in patients requiring supplemental oxygen at baseline,...
RHEA-AI
neutral
09/13/22 11:28 AM
Nasdaq : GILD
Gilead Foundation Awards $20 Million to Organizations Working to Advance Health Through Education Equity
Gilead Sciences, Inc. today announced that the Gilead Foundation' s Creating Possible Fund(TM) will provide a total of $20 million to 13 inaugural grantees. The Creating Possible Fund was launched to support creative and high-impact strategies that advance health through education equity, with a main focus on building a pipeline of Black health leaders.
RHEA-AI
positive
09/07/22 6:05 PM
Nasdaq : GILD
Trodelvy(R) Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study
Gilead Sciences, Inc. today announced the positive overall survival results from the Phase 3 TROPiCS-02 study evaluating Trodelvy (R) versus comparator chemotherapy in patients with HR+/ HER2- metastatic breast cancer who received endocrine-based therapies and at least two chemotherapies. These findings will be presented on Friday, September 9 at 4:20pm...
RHEA-AI
neutral
09/06/22 6:30 PM
Nasdaq : GILD
Kite's CAR T-cell Therapy Tecartus(R) Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
Kite, a Gilead Company, today announced that the European Commission has approved its CAR T-cell therapy Tecartus (R) for the treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. "This approval makes Tecartus the first and only CAR T-cell therapy indicated for this population of...
RHEA-AI
neutral
09/04/22 6:05 PM
Nasdaq : GILD
New TROPiCS-02 Data in HR+/HER2- Metastatic Breast Cancer Patients Demonstrates Progression-Free Survival Benefit of Trodelvy(R) Regardless of Their HER2 Status
Gilead Sciences, Inc. today announced new data from a post hoc subgroup analysis from the Phase 3 TROPiCS-02 study evaluating Trodelvy (R) versus comparator chemotherapies in patients with HR+/ HER2- metastatic breast cancer who progressed on endocrine-based therapies and at least two chemotherapies. Detailed findings will be presented at a mini-oral...
RHEA-AI
neutral